Evidence map›Paper›PMID 34652553›Full record

ArticleJournal of neuro-oncology2021

Systemic coagulation is activated in patients with meningioma and glioblastoma.

Swaroopa Yerrabothala, Brett L Gourley, James C Ford, Syed Rakin Ahmed, Stephen J Guerin, Marc Porter, Heather A Wishart, Marc S Ernstoff, Camilo E Fadul, Deborah L Ornstein

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Swaroopa Yerrabothala *Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Brett L Gourley *Rockwood Clinic, MultiCare Health System, Spokane, WA, USA.
James C FordDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Syed Rakin AhmedGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
Stephen J GuerinDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Marc PorterGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
Heather A WishartDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Marc S ErnstoffCancer Treatment and Diagnosis, Developmental Therapy Program, National Cancer Institute, Bethesda, MD, USA.
Camilo E FadulUniversity of Virginia School of Medicine, Charlottesville, VA, USA.
Deborah L OrnsteinDartmouth Hitchcock Medical Center, Lebanon, NH, USA. dlornstein@hitchcock.org.ORCID http://orcid.org/0000-0001-8011-1437
Dartmouth College · USBroad Institute · USMultiCare Health System · USNational Cancer Institute · USUniversity of Virginia · US

Funding

SYNERGY: The Dartmouth Center for clinical and Translational ScienceUL1TR001086 · NCATS · DARTMOUTH COLLEGE · PI GREEN, ALAN I · 2013 to 2017
$18.3M
NCATS NIH HHS UL1TR001086
6 · The paper itself

Abstract

purposeUp to 30% of patients with glioblastoma (GBM) develop venous thromboembolism (VTE) over the course of the disease. Although not as high, the risk for VTE is also increased in patients with meningioma. Direct measurement of peak thrombin generation (TG) allows quantitative assessment of systemic coagulation activation in patients with GBM and meningioma. Our aim was to determine the extent of systemic coagulation activation induced by brain tumors, to measure the shift between pre- and post-operative peak TG in patients with GBM, and to assess the relationship between pre-surgical peak TG and pre-operative brain tumor volume on imaging.

methodsPre- and post-surgical plasma samples were obtained from successive patients with GBM and once from patients with meningioma and healthy age- and sex-matched blood donor controls. TG was measured using the calibrated automated thrombogram (CAT) assay, and tumor volumes were measured in pre-surgical MRI scans.

resultsPre-surgical peak TG was higher in patients with GBM than in controls (288.6 ± 54.1 nM vs 187.1 ± 41.7 nM, respectively, P < 0.001), and, in the nine patients with GBM and paired data available, peak TG was significantly reduced after surgery (323 ± 38 nM vs 265 ± 52 nM, respectively, P = 0.007). Similarly, subjects with meningioma demonstrated higher peak TG compared to controls (242.2 ± 54.9 nM vs 177.7 ± 57.0 nM, respectively, P < 0.001). There was no association between peak TG and pre-operative tumor volume or overall survival.

conclusionOur results indicate that systemic coagulation activation occurs with both meningioma and GBM, but to a greater degree in the latter. Preoperative peak TG did not correlate with tumor volume, but removal of GBM caused a significant decrease in coagulation activation.

Indexed as

Blood CoagulationBrain NeoplasmsGlioblastomaMeningeal NeoplasmsMeningiomaHumansBrain tumorsCoagulation activationGlioblastoma multiforme (GBM)MeningiomaThrombin generation (TG)

Identifiers

PMID34652553
OpenAlexW3205309934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.